BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//REMEDi4ALL - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:REMEDi4ALL
X-ORIGINAL-URL:https://remedi4all.org
X-WR-CALDESC:Events for REMEDi4ALL
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Amsterdam
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Halifax
BEGIN:DAYLIGHT
TZOFFSETFROM:-0400
TZOFFSETTO:-0300
TZNAME:ADT
DTSTART:20230312T060000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0300
TZOFFSETTO:-0400
TZNAME:AST
DTSTART:20231105T050000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0400
TZOFFSETTO:-0300
TZNAME:ADT
DTSTART:20240310T060000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0300
TZOFFSETTO:-0400
TZNAME:AST
DTSTART:20241103T050000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0400
TZOFFSETTO:-0300
TZNAME:ADT
DTSTART:20250309T060000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0300
TZOFFSETTO:-0400
TZNAME:AST
DTSTART:20251102T050000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Asia/Tokyo
BEGIN:STANDARD
TZOFFSETFROM:+0900
TZOFFSETTO:+0900
TZNAME:JST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20231029T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240622
DTEND;VALUE=DATE:20240626
DTSTAMP:20260423T003130
CREATED:20240516T134216Z
LAST-MODIFIED:20240516T134216Z
UID:6717-1719014400-1719359999@remedi4all.org
SUMMARY:ICCBH 2024 - 11th International Conference on Children’s Bone Health
DESCRIPTION:This conference will bring together scientists\, clinicians\, trainees\, allied health professionals and others from a wide range of disciplines to gain a better understanding of the growing skeleton in relation to childhood health and disease and to discuss the most recent developments in clinical outcomes\, novel therapies\, and genetic discoveries. The conference scope ranges from basic molecular mechanisms to clinical aspects\, from bone pathophysiology to prevention and medical and surgical treatment. \nThis conference is for anyone with an interest in bone metabolism and bone mass in children\, adolescents and young adults to attend. \nThe ICCBH conference takes place every two years. The 2022 meeting in Dublin was attended by over 400 participants from across the globe\, making it truly multinational and multidisciplinary. \nThe scientific programme is designed to present researchers\, physicians\, and allied health professionals with the newest research\, with sessions including plenary lectures by world-leading experts\, symposia\, workshops\, oral abstract communications\, poster sessions and meet the expert sessions. The conference will offer investigators from around the world an opportunity to meet with each other and with industry representatives. \nICCBH 2024 is your opportunity to hear about and discuss the newest developments in our understanding of paediatric bone health. \nLearn more and register here.
URL:https://remedi4all.org/event/iccbh-2024-11th-international-conference-on-childrens-bone-health/
LOCATION:Salzburg Congress\, Auerspergstraße 6\, 5020 Salzburg\, Austria\, Salzburg\, Austria
ATTACH;FMTTYPE=image/png:https://remedi4all.org/wp-content/uploads/2024/05/Event-Page-Image-R4A-169-ratio-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Amsterdam:20240613T083000
DTEND;TZID=Europe/Amsterdam:20240613T180000
DTSTAMP:20260423T003130
CREATED:20240321T143124Z
LAST-MODIFIED:20240524T124322Z
UID:5924-1718267400-1718301600@remedi4all.org
SUMMARY:2nd MULTI-STAKEHOLDER MEETING - Ensuring patient centricity in Osteogenesis Imperfecta research
DESCRIPTION:REMEDi4ALL is hosting our 2nd Multi-stakeholder Meeting (MS) – Ensuring patient centricity in Osteogenesis Imperfecta (OI) research.\n  \nJoin the MSM\nREMEDi4ALL invites all stakeholders in the OI research community to join us for a day of learning\, discussion\, and inspiration. \nWe welcome clinicians\, academics\, patients and patient representatives\, pharmaceutical companies\, regulators\, payers\, health economists and all interested in OI and Rare Bone Diseases research. Together\, we will discuss and develop patient centric approaches to research and medicines development for OI. \nOur MSM will: \n\nShare information and advance learning\, in a pre-competitive and cooperative setting\nDevelop constructive dialogue between all stakeholders\nFacilitate collaboration and knowledge exchange\nIdentify current hurdles and propose solutions to ensure patient centricity in OI research\nPublish and disseminate the meeting outcomes to a broader community\n\n The Power of Patients\nThe patient’s voice is at the heart of this meeting. The OI community and the REMEDi4ALL Patient Advocacy Group have played integral roles in shaping the content and format of this event. \nWe wanted to ensure that the patients’ perspectives\, experiences\, and preferences guide our discussions and are at the forefront of OI research and therapeutic development. Over the day\, you will hear from numerous patients\, patients representative and advocates. They will: \n\nShare their personal journeys of living with OI\, providing insights into the day-to-day challenges they face\, as well as the triumphs and setbacks they encounter.\nHighlight unmet medical needs within the OI community\nDiscuss patient-relevant research questions and identify research priorities\n\nPatients will have the opportunities to \n\nLearn about the recent advancements in medicines development in OI\nInitiate collaborations and partnerships with all stakeholders\nActively participate and engage in scientific discussions about OI\n\nPatient centricity will run as a core-narrative in all our sessions and panel discussions\, encouraging each stakeholder to consider the patient perspective in their current and future work. \nAgenda (might be subject to change)\nWEDNESDAY\, 12 JUNE 2024\n\n\n\n19.30/20.00\nArrival and Speakers Dinner at the Hotel\nBY INVITATION ONLY\n\n\n\n THURSDAY\, 13 JUNE 2024 (8.30 – 18.00 CEST)\n\n\n\n8.00 – 8.30\nRegistration\n \n\n\n8.30 – 8.40\nOpening Ceremony and Welcome\nClaudia Fuchs (EURORDIS) \nLeonardo Panzeri (AS.IT.O.I.) \nDonald Lo (EATRIS)\n\n\n\nOpening Speech\n\n\n\n8.40 – 9.00\nWhat does it mean living with OI?\nGem Turner\n\n\n\nSESSION 1: Multi-national strategies for Patient Advocacy in OI\nModerators: Claudia Fuchs\n\n\n\n9.00 – 9.10\nThe European Reference Network on rare bone diseases (ERN-Bond)\nLuca Sangiorgi (Istituto Ortopedico Rizzoli)\n\n\n9.10 – 9.20\nThe European Registries for Rare Bone and Mineral Conditions (EuRR-Bone)\nClaudia Finis (DOIG (German Ostogenesis Imperfecta Organisation) and Berlin Institute of Health at Charité)\n\n\n9.20 – 9.30\nPatient Engagement Initiatives in Rare Diseases: an Italian Perspective\nAnnalisa Scopinaro (UNIAMO – Federazione Italiana Malattie Rare)\n\n\n9.30 – 9.45\nQ/A session\n\n\n\nPANEL DISCUSSION – Ask the Expert: How to become a Patient Advocate in OI?\nModerators: Marina O’Callaghan & Claudia Fuchs\n\n\n\nLightning talks: European and National Patient Engagement Activities in OI\n\n\n10.00 – 10.05\nStronger Together: OIFE’s Patient Engagement Initiatives\nAnna Rossi (OIFE)\n\n\n10.05 – 10.10\nIntroduction to Patient Engagement Activities in Italy\nSimona Paveri (AS.IT.O.I.)\n\n\n10.10 – 10.15\nIntroduction to Patient Engagement Activities in Norway\nInger-Margrethe Stavdal Paulsen (Norsk Forening for Osteogenesis Imperfecta)\n\n\n10.15 – 10.20\nIntroduction to Patient Engagement Activities in Spain\nMiguel Rodríguez Molina (Asociación Nacional Huesos de Cristal OI España – AHUCE)\n\n\n10.20 – 10.25\nBrittle Bone Society – Support that matters most\nPatricia Osborne (Brittle Bone Society – BBS)\n\n\n10.25 – 11.00\nPanel Discussion – Ask the Expert: How to become a Patient Advocate in OI?Panelists: Gem Turner\, Annalisa Scopinaro\, Anna Rossi\, Miguel Rodríguez Molina\, Patricia Osborne\, Emilija and Dace Liepina\, Marie Holm Laursen \n\n\n\n11.00 – 11.30 Coffee Break \n SESSION 2: Initiatives in the OI community \nModerators: Anna Rossi & Luca Sangiorgi \n\n\n\n11.30 – 11.40\nThe Impact Survey Initiative\nOliver Semler (University of Cologne)\n\n\n11.40 – 11.50\nAdult Health Initiative\nStuart Ralson (University of Edinburgh)\n\n\n11.50 – 12.00\nCare4BrittleBones Initiative Key4OI\nLida Zhytnik (Amsterdam UMC)\n\n\n12.00 – 12.15\nQ/A session\n\n\n\n SESSION 3: Current Treatment Options in OI – a multistakeholder perspective\nModerators: Anna Rossi & Luca Sangiorgi \n\n\n\n12.20 – 12.40 \nIntroduction to different treatment options and approaches for OI\nNick Bishop (The University of Sheffield)\n\n\n\n12.40  – 14.00 Lunch Break \nCONTINUATION SESSION 3 \n\n\n\nLightning talks: Current ongoing clinical trials with specific focus on challenges and opportunities of Patient Engagement\n\n\n14.00 – 14.10 \nREMEDi4ALL MOI-A Study\nJudith Cohen (University of Hull)\n\n\n14.10 – 14.20\nTOPaZ trial\nStuart Ralson (University of Edinburgh)\n\n\n14.20 – 14.30\nThe ORBIT  Phase 2/3 study: a collaborative design to study outcomes in OI\nLuigi Picaro (Mereo BioPharma) \n\n\n14.30 – 14.40 \nBOOSTB4 Trial: Boost Brittle Bones Before Birth\nCecilia Götherström (Karolinska Institute)\n\n\n14.40 – 14.55 \nQ/A session\n\n\n\n SESSION 4:”Patient-centered clinical trial design”\nModerators: Nick Bishop & Claudia Fuchs \n\n\n\nLightining talks: Patient perception and experience in clinical trials\n\n\n15.00 – 15.10\nPatient Perspective as a Teenager\nEmilija and Dace Liepina\n\n\n15.10 – 15.20\nPatient Experience on the ASTEROID Trial\nMarie Holm Laursen\n\n\n15.20 – 15.30 \nPatient Engagement activites within the R4ALL demonstrator (MOI-A Study)\nMarina O’Callaghan\n\n\n15.30 – 15.45 \nQ/A session\n\n\n\n15.45– 16.15 Coffee Break \nPANEL DISCUSSION – Innovative outcome measures in clinical trials\nModerators: Inger-Margrethe Stavdal Paulsennger & Claudia Fuchs  \n\n\n\nLightning talks: Quality of Life assessment (QoL) and patient related innovative outcome measures in clinical trials in OI\n\n\n16.15 – 16.25\nQoL assessment in OI\nNick Bishop (The University of Sheffield)\n\n\n16.25 – 16.35 \nDeveloping patient related outcome measures on mobility in rare bone disorders\nLuca Sangiorgi (Istituto Ortopedico Rizzoli)\n\n\n16.35 – 16.45\nRegulatory perspective on innovative outcome measures – how can patients contribute?\nVioleta Stoyanova-Beninska (Committee for Orphan Medicinal Products)\n\n\n16.45 – 16.55 \nPatient perspective on innovative outcome measure – how to advocate?\nInger-Margrethe Stavdal Paulsen (Norsk Forening for Osteogenesis Imperfecta)\n\n\n17.00 – 17.40 \nPanel Discussion – innovative outcome measures in clinical trials  \nPanelists: Nick Bishop\, Stuart Ralson\, Luigi Picaro\, Cecilia Götherström\, Oliver Semmler\, Lida Zhytnik\, Violeta Stoyanova-Beninska\n\n\n\n\n\n\n17.40 – 17.50\nPatient engagement in early Health Technology Assessment (eHTA)\nZsuzsanna Petyko (Syreon Research Institute)\n\n\n17.50 – 18.00\nWrap Up and Closing Remarks\nClaudia Fuchs (EURORDIS)\n\n\n\n18.00 Get Together \n FRIDAY\, 14 JUNE 2024 \n9.00 – 11.00 CEST\n\n\n\n9.00 – 11.00\nWorkshop on early Health Technology Assessment (eHTA)\nBY INVITATION ONLY \nDalma Hosszu (Syreon Research Institute)\n\n\n\n*Please note that only meals (lunch\, coffee breaks and get-together) are covered by the event organisers. Participants need to arrange their own travel and accomodation. \n Download the programme here. \nDownload the event flier here. \nSpeakers\nClick here to see the complete list of speakers and their bios. \nConfirmed speakers: \n \n  \nOrganisers\nOrganised within the REMEDi4ALL project in collaboration with EURORDIS – Rare Disease Europe\, Beacon for Rare Diseases\, Associazione Italiana Osteogenesi Imperfetta – AS.IT.O.I.\, Osteogenesis Imperfecta Federation Europe – OIFE\, European Reference Network on rare bone diseases – ERN BOND. \n \n  \nRegistration\nThis event will be a hybrid event\, hosted both online and in-person (Bologna\, Italy). Registration closes on 31 May\, 2024. \nRegister here
URL:https://remedi4all.org/event/2nd-multi-stakeholder-meeting-ensuring-patient-centricity-in-osteogenesis-imperfecta-research/
LOCATION:Savoia Hotel Regency\, Via del Pilastro\, 2\, Bologna\, Italy
ATTACH;FMTTYPE=image/jpeg:https://remedi4all.org/wp-content/uploads/2024/03/Slide2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Halifax:20240508T090000
DTEND;TZID=America/Halifax:20240508T143000
DTSTAMP:20260423T003130
CREATED:20240319T091036Z
LAST-MODIFIED:20240319T091036Z
UID:5904-1715158800-1715178600@remedi4all.org
SUMMARY:Clinical Pharmacology Guidances Advancing Drug Development and Regulatory Assessment
DESCRIPTION:ABOUT THIS EVENT\nThis public workshop will be hosted by the FDA Office of Clinical Pharmacology (OCP) and the University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI). The purpose of this workshop is to serve as a mechanism to engage with the public to share information on existing clinical pharmacology guidances and identify emerging scientific topics that might benefit from the development of scientific research and recommendations. \nBACKGROUND\nAt every step of drug development\, clinical pharmacology is applied to generate\, evaluate\, and use knowledge of drug disposition\, pharmacology\, and disease biology to progressively reduce regulatory uncertainty and inform public health decision-making.   Clinical pharmacology principles form the basis of dosage selection and optimisation and promote therapeutic individualisation by translating the knowledge of patient diversity into clinical recommendations for safe and effective use of medications.   Therefore\, having clear\, pragmatic\, and contemporary scientific recommendations to inform drug development and regulatory assessment is critical for the successful and efficient development of therapeutics that protect and promote public health. Developing new or revising existing guidance documents\, especially in the broad field of clinical pharmacology\, requires a unique and integrated approach centered around multistakeholder partnerships. \nWORKSHOP GOALS\n\n\nProvide an overview of scientific recommendations pertaining to clinical pharmacology applications during drug development and regulatory assessment. \n\n\nDiscuss the current scientific challenges and gaps in applying clinical pharmacology principles during drug development. \n\n\nIdentify potential opportunities and priorities for regulatory research and scientific guidance development from a clinical pharmacology perspective. \n\n\nAGENDA\nClick here to see the full agenda. \nREGISTRATION\nRegistration is free.  All interested parties are encouraged to register early. Please click here to register. \n\nClick here to learn more.
URL:https://remedi4all.org/event/clinical-pharmacology-guidances-advancing-drug-development-and-regulatory-assessment/
LOCATION:Online & in-person (Maryland\, United States)\, MD\, United States
ATTACH;FMTTYPE=image/png:https://remedi4all.org/wp-content/uploads/2024/03/Event-Page-Image-R4A-169-ratio.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Amsterdam:20240307T151500
DTEND;TZID=Europe/Amsterdam:20240307T170000
DTSTAMP:20260423T003130
CREATED:20231129T132411Z
LAST-MODIFIED:20240227T174130Z
UID:4267-1709824500-1709830800@remedi4all.org
SUMMARY:REMEDi4ALL Funders Network Meeting
DESCRIPTION:iDR24 Satellite Event – REMEDi4ALL Funders Network Meeting\nAfter the iDR24 the members and observers of the REMEDi4ALL Funders Network will come together to discuss the next steps of the network\, including the strategic agenda. \nRegister here\nLocation: Recinte Modernista de Sant Pau. Green auditorium. \nThis will be a hybrid event – possible to join online. \nAGENDA
URL:https://remedi4all.org/event/idr24-satellite-event-funders-network-meeting/
LOCATION:Recinte Modernista de Sant Pau\, Calle St. Antoni Maria Claret\, 167\, Barcelona\, Spain
ATTACH;FMTTYPE=image/png:https://remedi4all.org/wp-content/uploads/2023/11/FUNDERS-NETWORK-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Amsterdam:20240306T080000
DTEND;TZID=Europe/Amsterdam:20240307T180000
DTSTAMP:20260423T003130
CREATED:20231130T141140Z
LAST-MODIFIED:20231130T141233Z
UID:4280-1709712000-1709834400@remedi4all.org
SUMMARY:REMEDi4ALL #iDR24 International Drug Repurposing Conference
DESCRIPTION:Please see this page for more information: https://remedi4all.org/international-drug-repurposing-conference/
URL:https://remedi4all.org/event/remedi4all-idr24-international-drug-repurposing-conference/
LOCATION:Recinte Modernista de Sant Pau\, Calle St. Antoni Maria Claret\, 167\, Barcelona\, Spain
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Amsterdam:20231114T090000
DTEND;TZID=Europe/Amsterdam:20231114T173000
DTSTAMP:20260423T003130
CREATED:20230915T105013Z
LAST-MODIFIED:20231016T150222Z
UID:3297-1699952400-1699983000@remedi4all.org
SUMMARY:REMEDi4ALL MULTI-STAKEHOLDER MEETING: Drug Repurposing\, an Attractive Strategy in Pancreatic Cancer Treatment?
DESCRIPTION:REMEDi4ALL is pleased to announce the first Multi-Stakeholder Meeting on drug repurposing in PANCREATIC CANCER. \nThis one-day in person workshop is aimed to bring together all relevant key stakeholders (patients and patient representatives\, academia\, industry\, regulators\, funders\, etc.) to discuss the recent state of art on drug repurposing in oncology and specifically in pancreatic cancer. Topics of discussion will include an overview of the disease and the current (preclinical and clinical) drug repurposing programs\, biomarkers\, the importance of a patient-centred outcome measures and patient engagement activities in the study design and implementation. In addition\, current hurdles including financial and regulatory barriers to successfully repurpose non-oncology drugs in pancreatic cancer will also be discussed. \nREGISTER HERE \nPreliminary Agenda (might be subject to change) \n\n\n\n8.30 – 9.00 \nWelcome and Registration \n\n\n9.00 – 9.10  \nOpen Ceremony  \nClaudia Fuchs  (REMEDi4ALL – EURORDIS) \n\n\n SESSION 1: SETTING THE SCENE  \nModerator: Claudia Fuchs (REMEDi4ALL – EURORDIS)  \n\n\n9.10 – 9.30  \nGeneral Introduction on Pancreatic Cancer \nAlfredo Carrato (Pancreatic Cancer Europe – PCE)  \n\n\n9.30 – 9.50 \nTackling pancreatic cancer: tricks and tips \nIlse Rooman (Anticancer Fund\, Vrije Universiteit Brussels) \n\n\n9.50 – 10.10  \nDrug repurposing in oncology – Attractive but not that simple \nGauthier Bouche  (REMEDi4ALL – Anticancer Fund) \n\n\n10.10– 10.25 \nREMEDi4ALL  (vision\, mission\, European Context) \nDonald Lo  (REMEDi4ALL – EATRIS) \n\n\n10.25 – 11.10 \nPatient Perspective on Drug Repurposing in Oncology \nPatrycja Rzadkowska (Pancreatic Cancer Europe – PCE and DiCE)   \nAli Stunt (Pancreatic Cancer Europe – PCE and Pancreatic Cancer Action UK)   \n\n\n COFFE BREAK 11.10 – 11.40 \n\n\n SESSION 2: TREATMENT OPTIONS AND DRUG REPURPOSING OPPORTUNITIES IN PANCREATIC CANCER   \nModerators: Gauthier Bouche/Patricia Vandamme (REMEDi4ALL – Anticancer Fund)  \n\n\n11.40 – 12.00 \nOrphan Medicinal Products for the Treatment of Pancreatic Cancer: Lessons Learned From Two Decades of Orphan Designation \nVioleta Stoyanova-Beninska (Medicines Evaluation Board\, Chair of Committee for Orphan Medicinal Products at EMA) \n\n\n12.00 – 12.20  \nPreclinical and Clinical Updates on Drug Repurposing Opportunities in Pancreatic Cancer \nLuca Cardone  (Istituto Nazionale Tumori Regina Elena and National Research Council of Italy)  \n\n\n12.20– 12.40 \nPatient Story  \nSteve Bigelsen  (Rutgers New Jersey Medical School\, Newark\, NJ\, USA) \n\n\n12.40 – 13.00  \nThe VESPA Trial – Repurposing valproic acid combined with simvastatin to potentiate first line gemcitabine/nab-paclitxel-chemotherapy regimen in metastatic pancreatic cancer patients \nAlfredo Budillon (REMEDi4ALL – Istituto Nazionale Tumori Fondazione Pascale)  \n  \n  \n\n\n LUNCH BREAK 13.00 – 14.00  \n\n\n SESSION 3: THE PAST\, PRESENT AND FUTURE OF PANCREATIC CANCER CLINICAL TRIALS  \nModerators: Eve Hewitt/Rick Thompson (REMEDi4ALL- Beacon)  \n\n\n14.00 – 14.40 \nFinancial and Regulatory Barriers and Potential Solutions  \n– Overview on the current findings within REMEDi4ALL and future perspectives \n– Industry perspective  \n– Funders persepective \nHeleen van der Meer (REMEDi4ALL – ZonMW)  \nRaluca Radu  (REMEDi4ALL – Medicines for Europe)  \nHans Platteeuw  (CEO Galenicap)  \nAlexandre Bento Costa Alencar  (Rising Tide Foundation) \n\n\n14.40 – 15.00 \nBiomarkers in Pancreatic Cancer \nMaría Laura Garcia Bermejo  (Ramon & Cajal Health Research Institute) \n\n\n15.00 – 15.20 \nPatient Centricity in Clinical Trials  \nAntonella Cardone  (Cancer Patients Europe – CPE)  \nFederica Valsecchi  (Fondazione Valsecchi) \n\n\n COFFE BREAK 15.20 – 15.50   \n\n\n  \n15.50 – 17.20  \n FINAL ROUNDTABLE AND DISCUSSION  \nModerators: Claudia Fuchs (REMEDi4ALL – EURORDIS) – Rick Thompson (REMEDi4ALL – Beacon) \n\n\n17.20 – 17.30    \nClosing Remarks   \nClaudia Fuchs (REMEDi4ALL – EURORDIS)  \nRick Thompson (REMEDi4ALL – Beacon) \n\n\n17.30 \nEnd of the Meeting  and “GET TOGETHER”  \n 
URL:https://remedi4all.org/event/remedi4all-multi-stakeholder-meeting/
LOCATION:Nhow Brussels Bloom\, Rue Royale 250\, 1210\, Brussels\, Belgium
ATTACH;FMTTYPE=image/png:https://remedi4all.org/wp-content/uploads/2023/09/Banner-1st-MSM_v2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230924
DTEND;VALUE=DATE:20230929
DTSTAMP:20260423T003130
CREATED:20230227T175823Z
LAST-MODIFIED:20230227T175823Z
UID:1884-1695513600-1695945599@remedi4all.org
SUMMARY:FIP Brisbane 2023: Pharmacy building a sustainable future for healthcare – Aligning goals to 2030
DESCRIPTION:81ST FIP WORLD CONGRESS OF PHARMACY AND PHARMACEUTICAL SCIENCES\nThe pharmacist is key in assuring a safe and effective supply of medicines as well as their responsible use. As a direct provider of services\, from primary prevention and screening of diseases\, immunisations to therapeutic monitoring\, the work of this profession ensures that a patient’s medical therapy is appropriate\, the most effective\, the safest possible and the most convenient. \nThe International Pharmaceutical Federation (FIP) Development Goals align pharmacists’ education with societal and healthcare needs\, taking into consideration the path to universal health coverage and the UN Sustainable Development Goals\, and make the case for investing in the pharmacy workforce of tomorrow. \nThese goals present the profession with the direction for advancement and transformation and establishing its place within the healthcare system. By linking the FIP vision with a needs-based pharmaceutical workforce transformation programme\, a sustainable future for healthcare can be built — aligning goals to 2030. \nLinked to a healthier world\, the “Pharmacy building a sustainable future for healthcare — aligning the goals” theme sets out long-term goals and principles\, as well as short-term actions\, to transform the role and contribution of pharmacy. That transformation is required to maximise the health gain that healthcare systems derive from their interactions with the pharmacy profession. \nLearn more and register for the congress here.
URL:https://remedi4all.org/event/fip-brisbane-2023-pharmacy-building-a-sustainable-future-for-healthcare-aligning-goals-to-2030/
LOCATION:Brisbane\, Australia
ATTACH;FMTTYPE=image/png:https://remedi4all.org/wp-content/uploads/2023/02/Event-Page-Image-R4A-169-ratio-8.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Amsterdam:20230705T120000
DTEND;TZID=Europe/Amsterdam:20230705T140000
DTSTAMP:20260423T003130
CREATED:20230609T130126Z
LAST-MODIFIED:20230907T122723Z
UID:2156-1688558400-1688565600@remedi4all.org
SUMMARY:Workshop - REMEDi4ALL: what’s in it for funders?
DESCRIPTION:Learn and discuss how REMEDi4ALL & the funders network can support your funding activities in drug repurposing \nTarget audience: Funders who are (willing to be) active in drug repurposing  \nWithin REMEDi4ALL an international funders network for drug repurposing is currently being created by ZonMw. So far\, more than 50 different funders from all over the world have expressed their interest to join the network. Many of them also already shared their experiences with and ideas of funding drug repurposing with us via an online survey and in face-to-face interviews. This is the first workshop where funders who are interested in joining the funders network come together. Within an interactive setting we will talk about how REMEDi4ALL and the funders network can support funders in drug repurposing. You will learn about current and upcoming activities in REMEDi4ALL related to funders. Also\, we will share and discuss the insights collected from funders on the barriers\, solutions and incentives needed for funding drug repurposing.  \nDOWNLOAD THE EVENT SUMMARY \nDOWNLOAD THE FULL PRESENTATION \n\n\nYour browser does not seem to support iframes. Click here to read this PDF.\n    Created using FlowPaper Flipbook Maker ↗\n                \n            \n  \nAgenda \n\n\n\nTime \nTopic \n\n\n12.00-12.05 \nWelcome  \nChair: Heleen van der Meer (ZonMw) \n\n\n12.05-12.30 \nIntroduction REMEDi4ALL and funders network  \nAnton Ussi (EATRIS) & Heleen van der Meer (ZonMw) \n\n\n12.30-12.40 \nHow do you repurpose? REMEDi4ALL’s training programme for the whole repurposing ecosystem  \nRick Thomson (BEACON: for rare diseases) \n+ input from all participants \n\n\n  \n12.40-12.50 \nIntroduction to the REMEDi4ALL Funding Decision Tool  \nMarcell Csanadi (Syreon Research Institute)  \n+ input from all participants \n\n\n12.50-13.00 \nQ&A – break \n\n\n13.00-13.20 \nFunding drug repurposing: barriers\, solutions & incentives needed  \nHeleen van der Meer (ZonMw) \n\n\n13.20-13.45 \nPaneldiscussion  \nModerated by Pan Pantziarka (Anticancer Fund)  \nPanellists:  \n\nJoanna Davidge (LifeArc) \nTeun Grooters (Arega Medical) \nSagair Hussain (DEBRA) \nSarah Puddicombe (National Institute for Health and Care Research Coordinating Centre (NIHR CC)) \n\n\n\n\n13.45-14.00 \nNext steps for the funders network & closing  \nHeleen van der Meer (ZonMw)  \n+ input from all participants \n\n\n\n 
URL:https://remedi4all.org/event/workshop-remedi4all-whats-in-it-for-funders/
LOCATION:Online Event
ATTACH;FMTTYPE=image/png:https://remedi4all.org/wp-content/uploads/2023/06/R4A-3-002.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Amsterdam:20230628T100000
DTEND;TZID=Europe/Amsterdam:20230711T120000
DTSTAMP:20260423T003130
CREATED:20230608T080135Z
LAST-MODIFIED:20230614T091303Z
UID:2151-1687946400-1689076800@remedi4all.org
SUMMARY:Creating Health Impact from Research: Course of 3 Live Sessions
DESCRIPTION:If you are an Early Career Researcher who aims to enhance your skills to make an impact in healthcare research\, this course is for perfect you! \nSupported by the Wellcome Trust Institutional Translational Partnership Award (iTPA)\, we are working with UCL Academic Careers Office to sponsor UCL participants for this online course\, with the course fee fully covered. Register now to secure your spot as there is a limited quota available on a first-come-first-served basis. \nAbout this course\nThis course offers professional commercialization training for Higher Education Institutions across the UK. It consists of a series of live sessions accompanied by learning videos created by Pete Moores. \nIn this course\, you will: \n\nDevelop an impact hypothesis for your work\nDevelop your route to impact skills in three live\, online workshops\nGet practical support through an online community\n\n\nAbout the trainer\nPete is a consultant\, mentor\, coach and trainer in the translational field with a vast experience in working at the intersection of science and technology\, industry application and funding. He’s driven by a passion to create real-world benefits from new science and technology. \nHe has previously worked as a head coach on international training and mentoring programmes and has mentored\, coached\, and trained global researchers and entrepreneurs to develop strategic sales and marketing initiatives that unlock their innovation potential. \n\nLive Session Programme\n\nWednesday 28 June 2023\, 10:00-12:00\nBuilding a Bridge to the Market: the foundations of commercialisation\nWednesday 5 July 2023\, 10:00-12:00\nHow to Write a Successful Translational Research Application\nTuesday 11 July 2023\, 10:00-12:00\nCreating impact from scientific research\n\n\nWho is this course for?\nWe encourage Early Career Researchers (e.g. post-docs\, fellows and newly established lecturers) with an interest in delivering impact in healthcare research to sign up\, but this course is also open to any researcher who has not previously had translational-type project funding independent of their career stage. This course is NOT suitable for PhD or MRes students. If you have not engaged in any previous translational activity\, but are keen to do so\, this is the course for you! \n\nCourse Delivery\nThis workshop has been arranged by the University of Birmingham Translational Research Team\, together with a network of other Universities\, each supported by a Wellcome Trust Institutional Translational Partnership Award (iTPA). This event is part of an ongoing effort to support researchers in translating ground-breaking discovery research findings into practical improvements in human health. \nUCL participants will join the training sessions alongside researchers from the University of Birmingham\, and everyone will be encouraged to ask questions and network with fellow attendees. \n  \nLearn more and register here.
URL:https://remedi4all.org/event/creating-health-impact-from-research-course-of-3-live-sessions/
LOCATION:Online Event
ATTACH;FMTTYPE=image/png:https://remedi4all.org/wp-content/uploads/2023/06/Event-Page-Image-R4A-169-ratio.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230619
DTEND;VALUE=DATE:20230624
DTSTAMP:20260423T003130
CREATED:20221018T143020Z
LAST-MODIFIED:20221018T143020Z
UID:558-1687132800-1687564799@remedi4all.org
SUMMARY:Open Academy Schools 2023
DESCRIPTION:The Open Academy School on Medicines Research & Development is a training programme offered by\nEURORDIS\, designed to help participants become experts in medicines research and development. \nThe 2023 edition of the Open Academy Schools will take place in-person from 19-23 June in Barcelona. Schools are delivered in English in a blended format\, comprising e-learning modules\, pre-training webinars and face-to-face intensive days. Following a review of our training offerings\, we are excited to announce a new format for our in-person training. \nFrom 2023\, the face-to-face intensive week of the Open Academy School on Medicines Research & Development (formerly EURORDIS Summer School) and the Open Academy School on Scientific Innovation & Translational Research (formerly EURORDIS Winter School) will take place during the same week\, incorporating three days of parallel sessions and two days of joint sessions focusing on patient engagement across the whole life-cycle of a medicine. Greater knowledge sharing and networking opportunities will be fostered with both sets of trainees together during the week. \nThe new format will include off-site visits to research facilities\, greater contact time with faculty and EURORDIS staff and the chance to network with fellow patient advocates\, supporting each other in learning and practice during the training and beyond. \nClick here to learn more and to submit your application. The deadline for sending applications is on October 24.
URL:https://remedi4all.org/event/open-academy-schools-2023/
LOCATION:Barcelona
ATTACH;FMTTYPE=image/png:https://remedi4all.org/wp-content/uploads/2022/10/Open-Academy-Banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Amsterdam:20230512T133000
DTEND;TZID=Europe/Amsterdam:20230512T181500
DTSTAMP:20260423T003130
CREATED:20230512T091101Z
LAST-MODIFIED:20230512T091101Z
UID:2071-1683898200-1683915300@remedi4all.org
SUMMARY:Personalized Health Series - Workshop on Drug Repurposing
DESCRIPTION:The goal of this workshop series is to foster and strengthen partnerships and collaborations between industry and universities\, and to define a few pilot projects that are leading to innovation and societal impact. \nThis year’s edition will focus on Drug Repurposing. As in previous workshops\, the goal is to engage professionals from both academia and the pharma sector\, showing their joint initiatives with the aim to inspire new potential partnerships\, and to spark interdisciplinary and cross-functional interests. \nThe presentation of these join initiatives will be followed by the panel discussion “Harnessing the power of collaborations and partnerships”\, which will explore how to facilitate and accelerate partnerships and collaborations between academia and industry\, as well as how to remove obstacles to pave the way into impactful progess. \nAGENDA\n13:30 – 13:45 Welcome \n\nDr. Bram Stieltjes\, Head of Department Research & Analysis Services\, University Hospital\nBasel\, Chair of Personalized Health Basel\nDr. Raffaello Ferone\, Research Coordinator at Personalized Health Basel\nDr. Alessandro Mazzetti\, Team Lead\, Innovation Collaborations at Innovation Office\n\nCollaborations between Pharma companies and Academia \n13:45 – 14:10 Genome-assisted drug repurposing in psychiatry \n\nProf. Andreas Papassotiropulos\, University of Basel\n\n14:10 – 14:35 Combining Protein & Ligand Centric approaches to predict Drug Repurposing with in-silico\nPolypharmacology \n\nDr. Andrea Beccari\, Dompé farmaceutici S.p.A.\n\n14:35 – 15:00 REMEDi4ALL – the European platform for medicines repurposing & REMEDi4ALL Funders Network \n\nDr. Heleen van der Meer\, ZonMw\, and Dr. Anton Ussi\, EATRIS\n\n15:00 – 15:20 Break \n15:20 – 15:50 Pitching session \n\nSmall Molecules\, Big Opportunities: A Multi-Purpose Platform for Off-Target Analysis\nProf. Martin Smiesko\, University of Basel\nUsing implementation science to power the research pipeline towards faster transla-\ntion in real-world settings\nDr. Sabine Valenta\, Institute for Nursing Science\nHolistic Approach to Personalized Medicine & Host-Response Monitoring: Quantifying Pro-\ntein & Nucleic Acid Biomarkers with Diaxxo’s Desktop qPCR Platform\nEngr. Joseph Iwasyk\, Swiss TPH\nDrug repurposing for helminth infections\nProf. Jennifer Keiser\, Swiss TPH\nPicky Binders: choose the right predictor for your drug or target\nDr. Janani Durairaj\, University of Basel\n\n  \n15:50 – 17:10 Panel discussion: Harnessing the power of collaborations and partnerships: What is still needed in Drug Repurposing? From in-silico discoveries to business models – How to\nremove obstacles and facilitate and accelerate partnerships and collaborations? \nPanelists: Prof. Henriette Meyer zu Schwabedissen (University of Basel)\, Charlotte Piens\n(STADA Arzneimittel AG)\, Dr. Andrea Beccari\, (Dompé farmaceutici S.p.A.)\, Engr. Silvano\nColetti (CEO Chelonia Applied Science) Moderator: Dr. Benjamin Kasenda (Senior Consul-\ntant Medical Oncologist\, University Hospital Basel) \n17:10 – 18:15 Networking Apéro \n  \nOrganising Team:\n\nRaffaello Ferone (Personalized Health Basel) – raffaello.ferone@unibas.ch\nAlessandro Mazzetti (Innovation Office) – alessandro.mazzetti@unibas.ch
URL:https://remedi4all.org/event/personalized-health-series-workshop-on-drug-repurposing/
LOCATION:Innovation Office Garage\, Kreuzstrasse 4\, Allschwil
ATTACH;FMTTYPE=image/png:https://remedi4all.org/wp-content/uploads/2023/05/Event-Page-Image-R4A-169-ratio.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230322
DTEND;VALUE=DATE:20230325
DTSTAMP:20260423T003130
CREATED:20230317T081242Z
LAST-MODIFIED:20230317T081242Z
UID:1920-1679443200-1679702399@remedi4all.org
SUMMARY:DIA Europe 2023
DESCRIPTION:DIA EUROPE is the largest neutral event in the European life science industry – the knowledge hub between science\, healthcare\, and regulation. For it’s 35th anniversary\, DIA Europe is back in Basel\, where all thought leaders meet in person to discuss\, inspire\, and network. \nDIA Europe 2023 is designed to drive insights into action by connecting key policy discussions to real-world knowledge. Gathering innovative thought leaders from the entire life science landscape\, DIA will have 4 new content tracks in 2023: \n\nArtificial Intelligence and Data Science\nEU Health Policy and Regulatory Strategy\nMedical Devices and Combination Products\nProfessional Development\n\nLearn more about DIA EUROPE 2023 here.
URL:https://remedi4all.org/event/dia-europe-2023/
LOCATION:Basel\, Switzerland
ATTACH;FMTTYPE=image/png:https://remedi4all.org/wp-content/uploads/2023/03/Event-Page-Image-R4A-169-ratio.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230228
DTEND;VALUE=DATE:20230301
DTSTAMP:20260423T003130
CREATED:20230111T130858Z
LAST-MODIFIED:20230111T130858Z
UID:1026-1677542400-1677628799@remedi4all.org
SUMMARY:Rare Disease Day 2023
DESCRIPTION:Rare Disease Day – observed on the last day of February – aims to raise awareness for those living with a rare disease and their families and carers\, as well as help improve therapeutic options and access to treatments. \nAbout 3.5-5.9% of the world population (around 260-440 million people) is living with a rare disease. Those affected with a rare disease face specific challenges. Initial misdiagnosis and delay in diagnosis are common due to lack of scientific knowledge and varying symptoms between patients with the same rare disease. Additionally\, those living with a rare disease face difficulties in accessing quality treatments and care. \nREMEDi4ALL pursues the exploration of using existing medicines to address areas of unmet medical needs\, including the research of innovative repurposed medicines for targeted rare diseases.
URL:https://remedi4all.org/event/rare-disease-day-2023/
ATTACH;FMTTYPE=image/png:https://remedi4all.org/wp-content/uploads/2023/01/Event-Page-Image-R4A-169-ratio-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Asia/Tokyo:20230220T100000
DTEND;TZID=Asia/Tokyo:20230220T183000
DTSTAMP:20260423T003130
CREATED:20230110T102031Z
LAST-MODIFIED:20230110T102031Z
UID:994-1676887200-1676917800@remedi4all.org
SUMMARY:3rd PSTC Japan Safety Biomarker Workshop
DESCRIPTION:C-Path’s Predictive Safety Testing Consortium will be hosting its 3rd PSTC Japan Safety Biomarker Workshop on February 20\, 2023 in Fujisawa\, Japan. \nThe utilization of biomarkers in guiding drug development decisions through clinical trials and post marketing studies is increasing. This conference will explore the areas of cooperation in the clinical application of biomarkers and drug development tools and their qualification and share knowledge about safety biomarkers in drug development via speaker presentations and panel discussions. Representatives from academia\, government and industry will participate. The workshop is co-sponsored by The Japan Society of Toxicology. \nLearn more and register for the workshop here.
URL:https://remedi4all.org/event/3rd-pstc-japan-safety-biomarker-workshop/
LOCATION:Fujisawa\, Japan\, SHONAN HEALTH INNOVATION PARK 26-1\, Muraoka-Higashi 2-chome\, Fujisawa\, Kanagawa\, 251-8555\, Japan
ATTACH;FMTTYPE=image/png:https://remedi4all.org/wp-content/uploads/2023/01/Event-Page-Image-R4A-169-ratio-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Amsterdam:20230208T140000
DTEND;TZID=Europe/Amsterdam:20230208T153000
DTSTAMP:20260423T003130
CREATED:20230118T165249Z
LAST-MODIFIED:20230118T165249Z
UID:1202-1675864800-1675870200@remedi4all.org
SUMMARY:Webinar: Getting Started with Medicines Repurposing
DESCRIPTION:BEACON has partnered with LifeArc to help patient group leaders and academics team up to begin repurposing research on their specific rare condition. \nJoin us for a 3-part educational series that progresses through the drug repurposing journey using LifeArc’s newly developed Drug Repurposing toolkit that’s been designed with patient groups and academics in mind! \nIt takes a village to bring a licensed treatment to market\, especially when developing it from scratch. Drug repurposing provides hope. \nRegister now to learn how to navigate the drug repurposing landscape and bring a repurposed therapy to market! \nDates of 3-part educational series: 8th February\, 22nd February\, 8th March \nPlease note: This educational series is for leaders of rare disease patient groups and those within them that have a medical/scientific interest in drug development and repurposing. Academics who are thinking of getting involved in rare repurposing and research are highly encouraged to attend this series\, as it’s been designed specifically to benefit you!
URL:https://remedi4all.org/event/webinar-getting-started-with-medicines-repurposing/
ATTACH;FMTTYPE=image/png:https://remedi4all.org/wp-content/uploads/2023/01/Event-Page-Image-R4A-169-ratio-3.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Amsterdam:20230206T193000
DTEND;TZID=Europe/Amsterdam:20230206T210000
DTSTAMP:20260423T003130
CREATED:20230110T102034Z
LAST-MODIFIED:20230110T102034Z
UID:999-1675711800-1675717200@remedi4all.org
SUMMARY:Critical Path to Women Leading in Science
DESCRIPTION:On February 6\, C-Path is going to host a 90-minute roundtable discussing the Critical Path Institute’s programs and consortia\, highlighted by various women leaders at this public-private partnership. The team will discuss how C-Path contributes to transforming and accelerating the medical product development process\, as well as their personal professional development journey. The roundtable will include an interactive Q&A session\, where the audience can ask specific questions about C-Path activities and\, more generally\, scientific career paths. \nLearn more and register here.
URL:https://remedi4all.org/event/critical-path-to-women-leading-in-science/
LOCATION:Online Event
ATTACH;FMTTYPE=image/png:https://remedi4all.org/wp-content/uploads/2023/01/image.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Amsterdam:20230118T160000
DTEND;TZID=Europe/Amsterdam:20230118T180000
DTSTAMP:20260423T003130
CREATED:20230109T134147Z
LAST-MODIFIED:20230109T134147Z
UID:965-1674057600-1674064800@remedi4all.org
SUMMARY:Informed and Shared Decision-Making Webinar
DESCRIPTION:Health literacy\, patient empowerment\, shared decision-making and patient involvement are no buzzwords\, but major cornerstones of a successful\, efficient and effective patient-centred healthcare. All patients have the right to receive accurate information about their cancer\, their different treatment options and the potential side effects. \nThe Anticancer Fund has been involved in the cancer literacy-topic within the Inequalities Network of the European Cancer Organisation. Both organisations worked on a paper recently published in the Journal of Cancer Policy: “Cancer literacy – Informing patients and implementing shared decision making”. The article highlights the importance of health literacy to empower patients in their journey through treatment and gives several recommendations for improving cancer literacy in Europe. \nBuilding on this paper\,  the Anticancer Fund and the European Cancer Organisation are co-hosting a webinar gathering cancer patients\, caregivers\, healthcare professionals and policymakers. Participants will be sharing their perspective on ‘Well-informed and shared decision-making in oncology – why is it important and how can we make it happen?” The event aims to illustrate to key policy- and decision-makers\, the value and benefit of reliable information when it comes to taking real steps in bettering cancer care. \nThe webinar will be co-chaired by Kathy Oliver\, Chair and founding Co-Director of the International Brain Tumour Alliance (IBTA) – Co-Chair\, E.C.O. Patient Advisory Committee\, and Guy Buyens\, Medical Director\, Anticancer Fund – Contributor to E.C.O.’s Community 365. \nLearn more about the webinar and register as an attendee here. \n 
URL:https://remedi4all.org/event/informed-and-shared-decision-making-webinar/
LOCATION:Online Event
ATTACH;FMTTYPE=image/png:https://remedi4all.org/wp-content/uploads/2023/01/Event-Page-Image-R4A-169-ratio.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221130
DTEND;VALUE=DATE:20221201
DTSTAMP:20260423T003130
CREATED:20221010T153211Z
LAST-MODIFIED:20221010T153643Z
UID:529-1669766400-1669852799@remedi4all.org
SUMMARY:VALUE ADDED MEDICINES CONFERENCE #VAM22
DESCRIPTION:The 4th Value Added Medicines Conference – #VAM22 – takes place on 30 November 2022 in Brussels (Belgium). The theme this year is “Giving medicines a new life”. \nValue Added Medicines (VAMs) present an opportunity to bring treatments for indications with no approved therapies and improve existing ones. They can reduce unmet medical need (repurposing/repositioning)\, optimise existing medicines to allow for patient-centric design or address healthcare inefficiencies (reformulation) and combine medicines or substances with digital services or devices to substantially improve treatment outcomes (complex combinations). \nIn Europe\, there is significant untapped potential in innovation on existing therapies\, providing an opportunity for patients\, healthcare providers\, payers\, industry and healthcare systems. Re-evaluating the current innovation model should lead to greater focus on ways to stimulate innovation across the lifecycle of medicines and especially on off-patent molecules. \nTo promote an innovation ecosystem that focuses on relevant benefits to society\, we need to consider some fundamental changes in the way innovation is currently fostered and evaluated. The pharmaceutical industry is transforming to continuously bring value to patients through sustained innovation in off-patent medicines. \n\nHow can VAMs address some of the key healthcare challenges of today?\nHow can the value of VAMs be captured for society?\nHow are we advancing medicine repurposing in Europe?\nHow could we shape an EU environment that supports continuous treatment improvements? How does continuous innovation fit into the broader EU agenda to bolster access to treatment and innovation?\n\nThe Value Added Medicines Conference will gather a wide range of experts in the healthcare community to share best practices and discuss patient access to continuous innovation. Come and join us to learn more about Value Added Medicines and to discuss the current environment\, challenges\, and opportunities in Europe.
URL:https://remedi4all.org/event/value-added-medicines-conference-vam22/
LOCATION:Thon Hotel Eu\, Brussels\, Rue d'Arlon 81\, Brussels\, Belgium
ATTACH;FMTTYPE=image/jpeg:https://remedi4all.org/wp-content/uploads/2022/10/Fed9jRgWAAEnNkC.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221122
DTEND;VALUE=DATE:20221124
DTSTAMP:20260423T003130
CREATED:20221103T131313Z
LAST-MODIFIED:20221103T131313Z
UID:675-1669075200-1669247999@remedi4all.org
SUMMARY:Broad-spectrum anti-viral therapeutics: A key tool for pandemic preparedness
DESCRIPTION:The workshop “Broad-spectrum anti-viral therapeutics: A key tool for pandemic preparedness” is going to take place on 22 and 23 November 2022 in Brussels\, Belgium. \nThe workshop will be focusing on the following aspects: \n\nBroad-spectrum antivirals in pandemic preparedness & response\nCOVID-19 and pandemic preparedness\nPre-clinical research of broad-spectrum antivirals\nClinical research environment\nAvailability & Access\nGlobal context\n\nThis high-level workshop is organized by “VO Communication” and the European Commission. \nYou can find the detailed workshop agenda here\, as well as the background scoping paper here.
URL:https://remedi4all.org/event/broad-spectrum-anti-viral-therapeutics-a-key-tool-for-pandemic-preparedness/
LOCATION:The Comet Louise Place Stéphanie 20\, Brussels\, Belgium
ATTACH;FMTTYPE=image/png:https://remedi4all.org/wp-content/uploads/2022/11/Event-Page-Cover-banner-size-6.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221114
DTEND;VALUE=DATE:20221118
DTSTAMP:20260423T003130
CREATED:20221028T070424Z
LAST-MODIFIED:20221028T070424Z
UID:605-1668384000-1668729599@remedi4all.org
SUMMARY:World Orphan Drug Congress Europe 2022
DESCRIPTION:STRATEGY\, ADVOCACY & PARTNERING FOR THE GLOBAL ORPHAN DRUG INDUSTRY \nThe World Orphan Drug Congress is an award-winning event with an exhibition that has grown to become the largest and most established orphan drugs & rare diseases meeting of its kind across the globe. \nNow in its 13th annual edition\, the World Orphan Drug Congress Europe\, together with the co-located Cell & Gene Therapy Congress\, will continue to bring experts from the whole value chain under one roof\, where you get to meet decision makers in the areas that are most applicable for your business offering. \nThree REMEDi4ALL partners will be joining the congress as speakers. On the afternoon of 16 November\, Anton Ussi (Operations & Finance Director for EATRIS ERIC) will be taking part in the panel discussion “Together4RD – Multi-stakeholder initiative to unlock ERN collaboration with industry”. Additionally\, on the morning of 17 November\, Eva Molero (Chief Executive Officer at Teamit Research) and  Rick Thompson (Chief Executive Officer at Beacon) will be participating in the panel discussion “The evolving world of drug repurposing”. \nClick here to see the full agenda. Register for the event here.
URL:https://remedi4all.org/event/world-orphan-drug-congress-europe-2022/
LOCATION:MELIA SITGES HOTEL\, Sitges\, Barcelona\, Spain
ATTACH;FMTTYPE=image/png:https://remedi4all.org/wp-content/uploads/2022/10/Event-Page-Cover-banner-size-3.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221114
DTEND;VALUE=DATE:20221116
DTSTAMP:20260423T003130
CREATED:20220819T095738Z
LAST-MODIFIED:20220819T095738Z
UID:235-1668384000-1668556799@remedi4all.org
SUMMARY:Drug Repositioning and Repurposing Conference
DESCRIPTION:Join us at the 10TH ANNUAL DRUG REPOSITIONING AND REPURPOSING CONFERENCE\, where attendees will meet and learn from the world’s foremost experts in the fields of repositioning and repurposing. As the Single Longest-Running Conference in the Space\, Arrowhead Publishers’ annual event continues to be the “go to” meeting for pharma executives\, academicians\, researchers and patient advocacy groups who want to keep abreast of new developments in the field\, learn from experts and meet possible collaborators and partners. \nKey Subjects Covered at This Event\nPatient Advocacy Efforts\nEmphasis on and engagement with patient advocacy groups\, who are investing in drug repositioning efforts to an unprecedented degree. \nNew Partnerships\nThe conference will explore how new partnerships between various groups\, including government\, industry and academia are advancing repurposing. \nSystematic Repositioning & Data Analytics\nRepurposing is no longer based on serendipity as more and more companies are designing tools to streamline and increase the odds of success. \nCutting-Edge Technologies\nArtificial intelligence and other technologies are quickly reshaping drug discovery and development. This event will showcase how they are reshaping the field of drug repurposing. \nRegulatory and Legal Guidance\nLegal\, IP and regulatory guidance will be shared with the audience\, including knowlege and insight into the 505(b)(2) regulatory pathway. \nKey Therapeutic Areas for Repurposing\nRepurposing is beginning to make its mark in a range of therapeutic areas in need of new therapies. Rare and orphan diseases\, tropical diseases and cancer will be discussed in terms of repurposing efforts currently underway.
URL:https://remedi4all.org/event/drug-repositioning-and-repurposing-conference/
LOCATION:Westin Arlington Gateway\, 801 North Glebe Road\, Arlington\, VA\, 22203\, United States
ATTACH;FMTTYPE=image/jpeg:https://remedi4all.org/wp-content/uploads/2022/08/header2021-drug-repurpose-1.jpg
ORGANIZER;CN="Arrowhead Publishers":MAILTO:enquiries@arrowheadpublishers.com
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Amsterdam:20221019T120000
DTEND;TZID=Europe/Amsterdam:20221020T123000
DTSTAMP:20260423T003130
CREATED:20221020T075537Z
LAST-MODIFIED:20221020T152437Z
UID:568-1666180800-1666269000@remedi4all.org
SUMMARY:Advanced Course in Network Medicine
DESCRIPTION:KI NMA is proud to invite you to participate in an advanced course in Network medicine – “From byte to bench to bed side – addressing large and complex data sets in biomedicine”. \n\nThe advanced course in network medicine “From byte to bench to bed side – addressing large and complex data sets in biomedicine” will be held both at Neo (Campus Flemingsberg) and streamed online.\n\n\nThe course is aimed towards PhD students\, postdocs\, researchers and everyone else that wants to learn more about the topic of network medicine\, its application and implementation. \nThe course will start with a key note speaker\, Professor Ed Silverman\, Channing Division of Network Medicine\, Brigham and Wome’s Hopital/Harvard Medical School\, and the following session of the course will see lecture given by distinguished scientist from Europe and Sweden. The sessions will be followed by panel debates on the pros and cons\, and the innovative potential of Network Medicine. \nUpdated program. Registration is now closed. \n\n 
URL:https://remedi4all.org/event/advanced-course-in-network-medicine/
LOCATION:Campus Flemingsberg & Online
ATTACH;FMTTYPE=image/jpeg:https://remedi4all.org/wp-content/uploads/2022/10/52955-landscape-full-width-2x.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20221010T090000
DTEND;TZID=Europe/London:20221010T180000
DTSTAMP:20260423T003130
CREATED:20220824T081813Z
LAST-MODIFIED:20220824T081813Z
UID:277-1665392400-1665424800@remedi4all.org
SUMMARY:Drug Repurposing for Rare Diseases 2022
DESCRIPTION:We are delighted to announce our ninth annual Drug Repurposing for Rare Diseases Conference and\, for the first time since 2020\, it’s returning live and in-person! \nOur annual conference\, Drug Repurposing for Rare Diseases\, highlights the role that drug repurposing can play in lowering the cost and accelerating the development of rare disease treatments. \nAn event unique in its collaborative and multi-stakeholder focus\, we bring patient groups\, researchers and industry professionals together to showcase excellent examples of rare repurposing. \nDrug Repurposing for Rare Diseases sparks cross-sector conversation\, uniting the expertise of diverse groups to inspire meaningful\, patient-centred drug repurposing research for rare diseases.
URL:https://remedi4all.org/event/drug-repurposing-for-rare-diseases-2022/
LOCATION:America Square Conference Centre\, 17\, One Crosswall\, America Square\, Londen\, EC3N 2LB\, United Kingdom
ATTACH;FMTTYPE=image/png:https://remedi4all.org/wp-content/uploads/2022/08/Maisha.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20220916T000000
DTEND;TZID=Europe/London:20220916T180000
DTSTAMP:20260423T003130
CREATED:20220819T094616Z
LAST-MODIFIED:20220819T094616Z
UID:230-1663286400-1663351200@remedi4all.org
SUMMARY:CeBIL Annual Symposium 2022 - Intellectual Property and Drug Repurposing: New Frontiers
DESCRIPTION:Repurposing\, the idea of finding new treatments for already authorised drugs\, presents significant advantages for drug development. Modern drug development is hindered by high costs and research that takes over a decade. \nRepurposing is a potential solution to these problems because it is cheaper\, faster and safer than developing new compounds. However\, academics\, policymakers and industry experts argue that repurposing is underutilised\, pointing at gaps in patent and pharmaceutical law that make it financially unviable. \nThe symposium will focus on important policy issues for pharmaceutical repurposing. In particular\, it will examine new empirical data on patent protection\, regulatory exclusivities and market authorisation pathways. It will also discuss two new public sector repurposing initiatives launched in the UK and EU\, and investigate other policy frontiers. It will have a hybrid format\, with both in-person and online only tickets available. \nThe 2022 CeBIL Symposium is organised by the Cambridge Centre for Law\, Medicine and Life Sciences (LML) in combination with the Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) at the University of Copenhagen. The Symposium is generously supported by the Novo Nordisk Foundation. \nHosted by the University of Cambridge\, an international hub for legal and scientific expertise\, we hope the event will stimulate discussion between legal\, economic\,business\, medical\, and scientific experts at a range of career stages. \nConfirmed participants include: \n\nProf. Timo Minssen (CeBIL\, University of Copenhagen)\nProf. Kathleen Liddell (LML\, University of Cambridge)\nProf. Mateo Aboy (LML\, University of Cambridge)\nDr Jakob Wested (CeBIL\, University of Copenhagen & Danish Medicines Agency)\nMs Eugenia Wachters (Healx)\nDr Anita Marguerie de Rotrou (Office for Translational Research\, University of Cambridge)\nMr Adrian Freeman (AstraZeneca)\nProfessor Ken Shadlen (London School of Economics)\nDr John Liddicoat (LML\, University of Cambridge)\nDr Rosemary Lovett (Medicines Repurposing Programme\, NHS England)\nDr Charlotte Asker-Hagelberg (Swedish Medical Products Agency)\nDr Julian Huppert (Intellectual Forum\, Jesus College\, University of Cambridge)\nDr Marco Schito (Critical Path Institute)\nMr Paul Fleming (British Generic Manufacturers Association)\nMs Jacqueline Mulryne (Arnold & Porter)\nProf. Sir Munir Pirmohamed (NHS Chair of Pharmacogenetics & University of Liverpool)\n\nThe CeBIL Symposium will coincide with the EPIP Annual Conference in Cambridge (14-16 September 2022).
URL:https://remedi4all.org/event/cebil-annual-symposium-2022-intellectual-property-and-drug-repurposing-new-frontiers/
LOCATION:Newnham College\, University of Cambridge\, Sidgwick Avenue\, Cambridge\, CB3 9DF\, United Kingdom
ATTACH;FMTTYPE=image/jpeg:https://remedi4all.org/wp-content/uploads/2022/08/https-cdn.evbuc_.com-images-286046919-82449972845-1-original.20220517-090934.jpeg
ORGANIZER;CN="Centre for Law%2C Medicine and Life Sciences%2C University of Cambridge":MAILTO:lml@law.cam.ac.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Amsterdam:20220902T080000
DTEND;TZID=Europe/Amsterdam:20220903T170000
DTSTAMP:20260423T003130
CREATED:20220818T141600Z
LAST-MODIFIED:20220818T141600Z
UID:224-1662105600-1662224400@remedi4all.org
SUMMARY:REXPO22 – 1st international conference on drug repurposing
DESCRIPTION:The REPO4EU Horizon Europe project to build a European/Global Platform for Drug Repurposing will kick off with the 1st International Conference on Drug Repurposing. \nRExPO22 is the first instalment in the RExPO annual conference series and will take place in Maastricht\, the Netherlands. \nREPO4EU and RExPO22 have partnered with professional societies\, companies\, patent attorneys\, legal and ethics experts\, clinical research organisations\, regulators\, payers\, patient representatives and many more! We have multiple collaborations around the world that pool together their knowledge and know-how to deliver the best possible outcome in the single major opportunity in drug development\, i.e drug repurposing. \nThe speakers include Anton Ussi\, EATRIS Operations and Finance Director\, who will also co-chair the conference. \nFind out more and see the agenda here. Abstract submission is still open here.
URL:https://remedi4all.org/event/rexpo22-1st-international-conference-on-drug-repurposing/
LOCATION:The Function Hall\, Maastricht\, 6229 EP\, Netherlands
ATTACH;FMTTYPE=image/jpeg:https://remedi4all.org/wp-content/uploads/2022/08/https-cdn.evbuc_.com-images-294342909-989138366703-1-original.20220531-085337.jpeg
ORGANIZER;CN="RePo4EU":MAILTO:rexpo@repo4.eu
END:VEVENT
END:VCALENDAR